Further, encenicline is so far the only compound targeting the α7-nAChR that has been evaluated in a large-scale clinical phase 3 trial in schizophrenia patients, but no effect could be seen (Brannon, 2019) [see review by Terry and Callahan (2020)]. This evidence concerns the gene CHRNA7 and schizophrenia.